Is Bluejay Diagnostics struggling financially?

Yes, by its own account. Bluejay Diagnostics told the SEC on 7 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector: Biotech/Pharma
Market cap: $4.1M
Source filing: 10-Q 7 May 2026
Balance sheet: 30 Jun 2026

Cash runway

15months

If the burn speeds up

Empty by Sep 2027
22months

If it eases off

Empty by Apr 2028

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$9.6M

Cash burned over the last 12 months

$6.2M

What Bluejay Diagnostics told the SEC

…These financial results and financial position, and the Company’s expected forward-looking outlook of significant negative cash flow in the future, raise substantial doubt with respect to its ability to continue as a going concern. The Company expects that it will not be in position to submit a 510(k) regulatory application to the FDA for Symphony until at least 2027, if it is even able to generate sufficient…

Bluejay Diagnostics, Inc., Form 10-Q, filed 7 May 2026.

Read the filing on SEC.gov

What this means

Not a bankruptcy filing, and not a prediction.
It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

57.8% share-count increase The company issued stock. Each share now owns 36.6% less of the business than a year ago, before any change in the price.
Cash burn is narrowing It is spending 51% less cash per year than it was, so the runway above is lengthening rather than shortening.

Cash runway

The runway math

What Bluejay Diagnostics told the SEC

What this means

What else the numbers show

Other Biotech/Pharma companies that filed the doubt